<DOC>
	<DOCNO>NCT01525394</DOCNO>
	<brief_summary>This double-blind ( vis-a-vis lenvatinib ) , randomize , placebo-controlled , three-treatment , three-way crossover study healthy subject . There two phase study : Pre-Randomization Randomization . The Pre-Randomization Phase consist Screening Baseline Period 1 . The Randomization Phase consist five period : Treatment Period 1 , Baseline Period 2 , Treatment Period 2 , Baseline Period 3 , Treatment Period 3 . Completion study termination procedure perform Visit 11 .</brief_summary>
	<brief_title>A Double-Blind Study Healthy Volunteers Assess Effect E7080 QTc Interval</brief_title>
	<detailed_description />
	<mesh_term>Lenvatinib</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>Subjects must meet follow criterion include study : 1 . Normal , healthy male female subject great equal 18 year age time informed consent . 2 . All female must negative serum human chorionic gonadotropin ( hCG ) pregnancy test result Screening Baseline . Females childbearing potential must agree use medically acceptable method contraception ( e.g. , abstinence , intrauterine device ( IUD ) , doublebarrier method condom + spermicide condom + diaphragm spermicide , contraceptive implant , oral contraceptive vasectomized partner ) throughout entire study period 30 day study drug discontinuation . The subject exempt requirement postmenopausal woman ( define great age 50 least 12 month amenorrhea ) subject sterilize surgically otherwise prove sterile ( e.g. , bilateral tubal ligation surgery least 6 month prior dose , hysterectomy , bilateral oophorectomy surgery least 2 month prior dose ) . All woman reproductive potential use hormonal contraceptive must stable dose hormonal contraceptive product least 12 week prior dose must continue use contraceptive study 30 day study drug discontinuation . 3 . Male patient abstinent undergone successful vasectomy , partner woman childbearing potential must use , partner must use highly affective method contraception ( e.g. , condom + spermicide , condom + diaphragm spermicide , IUD ) start least one menstrual cycle prior start study drug ( ) throughout entire study period 30 day ( longer appropriate ) last dose study drug . Those partner use hormonal contraceptive must also use additional approve method contraception ( describe previously ) . 4 . Partners male female subject must use effective method contraception ( e.g. , barrier method , IUD ) , commence prior initiation study drug continue duration study 30 day study drug discontinuation . All female reproductive potential use hormonal contraceptive must stable dose hormonal contraceptive product least 12 week prior dose must continue use contraceptive study 30 day study drug discontinuation . 5 . Voluntarily provide write informed consent prior study procedure . 6 . Are willing able comply aspect protocol duration study . Subjects meet follow criterion exclude participation study : 1 . Subjects clinically significant abnormality , include QTc interval great 450 msec , 12lead ECG time Screening Period , Baseline Periods , 30 minute administration study drug . 2 . A history myocardial infarction , syncope cardiac arrhythmia . 3 . A history uncontrolled hypertension , define systolic pressure great 140 mm Hg diastolic pressure great 90 mm Hg . 4 . A history unstable heart disease additional risk factor Torsades de Pointes ( TdP ) include heart failure , hypokalemia , family history congenital long QT syndrome unexplained cardiac arrest . 5 . Subjects history gastrointestinal surgery ( hepatectomy , nephrotomy , digestive organ resection , etc . ) may affect PK profile lenvatinib . 6 . Known intolerance study drug moxifloxacin ( Avelox ) ( excipients ) . 7 . A positive result human immunodeficiency virus ( HIV ) , hepatitis A antibody ( HAVAb ) , hepatitis B surface antigen ( HBsAg ) hepatitis C antibody ( HCVAb ) test Screening . 8 . A known suspected history drug alcohol misuse within 6 month prior Screening , positive urine drug test breath alcohol test Screening . 9 . Subjects participate another clinical trial investigational drug device within 4 week prior dose . 10 . Subjects receive blood product within 4 week , donate blood within 8 week , donate plasma within one week dosing . 11 . Subjects engage heavy exercise within 2 week prior checkin ( e.g. , marathon runner , weight lifter , etc. ) . 12 . Females pregnant breastfeeding . 13 . Subjects unwilling unable abide requirement study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>lymphoma</keyword>
	<keyword>Refractory solid tumor</keyword>
</DOC>